207233-99-6

Usage

Uses

Used in Pharmaceutical Industry:
2,5-DIMETHYL-1-(3-(TRIFLUOROMETHYL)-PHENYL)PYRROLE-3-CARBOXALDEHYDE, 99 is used as a benzodiazepine antagonist for the reversal of sedative and anxiolytic effects of benzodiazepine drugs. It is particularly useful in cases of overdose or during anesthesia recovery, where it can help restore alertness and consciousness.
Used in Clinical Settings:
In clinical settings, 2,5-DIMETHYL-1-(3-(TRIFLUOROMETHYL)-PHENYL)PYRROLE-3-CARBOXALDEHYDE, 99 is used as an antidote for benzodiazepine overdose, helping to counteract the life-threatening effects of excessive benzodiazepine consumption.
Used in Research Laboratories:
2,5-DIMETHYL-1-(3-(TRIFLUOROMETHYL)-PHENYL)PYRROLE-3-CARBOXALDEHYDE, 99 is used in research laboratories for the development of medications and the study of neurotransmitter receptors. Its ability to block benzodiazepine receptors makes it a valuable tool for understanding the mechanisms of action of these drugs and for developing new therapeutic agents.

InChI:InChI=1/C14H12F3NO/c1-9-6-11(8-19)10(2)18(9)13-5-3-4-12(7-13)14(15,16)17/h3-8H,1-2H3

Upstream product

• 110-13-4 2,5-hexanedione 
• 98-16-8 3-trifluoromethylaniline 
• 570-04-7 2,5-dimethyl-1-(3-(trifluoromethyl)phenyl)-1H-pyrrole 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 1428183-47-4 C₂₂H₂₁F₃N₂O₃ 

Relevant academic research and scientific papers

Synthesis, structure and in vitro anti-trypanosomal activity of non-toxic arylpyrrole-based chalcone derivatives

With an intention of identifying chalcone derivatives exhibiting anti-protozoal activity, a cohort of relatively unexplored arylpyrrole-based chalcone derivatives were synthesized in moderate to good yields. The resultant compounds were evaluated in vitro for their potential activity against a cultured Trypanosoma brucei brucei 427 strain. Several compounds displayed mostly modest in vitro anti-trypanosomal activity with compounds 10e and 10h emerging as active candidates with IC50 values of 4.09 and 5.11 μM, respectively. More importantly, a concomitant assessment of their activity against a human cervix adenocarcinoma (HeLa) cell line revealed that these compounds are non-toxic.

ANDROGEN RECEPTOR ANTAGONISTS

Compounds that inhibit the androgen receptor, pharmaceutical compositions comprising one or more of the compounds, as well as methods of treating cancer using such compounds are described.

Discovery and optimisation studies of antimalarial phenotypic hits

There is an urgent need for the development of new antimalarial compounds. As a result of a phenotypic screen, several compounds with potent activity against the parasite Plasmodium falciparum were identified. Characterization of these compounds is discussed, along with approaches to optimise the physicochemical properties. The in vitro antimalarial activity of these compounds against P. falciparum K1 had EC50 values in the range of 0.09e29 mM, and generally good selectivity (typically >100-fold) compared to a mammalian cell line (L6). One example showed no significant activity against a rodent model of malaria, and more work is needed to optimise these compounds.